A 6-Month Open Pilot Study to Investigate the Safety and Tolerability of Immediate Conversion From Calcineurin Inhibitor Tacrolimus to Everolimus in Stable Maintenance Renal Transplant Recipients.
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Renal transplant rejection
- Focus Adverse reactions
- Acronyms HERMES
- Sponsors Novartis Pharmaceuticals
- 23 Feb 2017 Planned End Date changed from 1 Jun 2009 to 1 Aug 2008.
- 23 Feb 2017 Status changed from suspended to withdrawn prior to enrolment.
- 06 Jan 2011 New trial record